Sukhjit Brar
Child & Adolescent Psychiatry · Fresno, CANPI 1194037325
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $228,958 of the $282,722 with a category attached, or 81.0%. Teva Pharmaceuticals USA, Inc. accounts for 75.8% of it on its own, with 9 other manufacturers making up the rest. Among child & adolescent psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $900.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$214K
- Otsuka America Pharmaceutical, Inc.$66K
- Alkermes, Inc.$826
- Johnson & Johnson$646
- E.r. Squibb & Sons, L.L.C.$240
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$163
- plus $455 from 4 others
What the payments were for
- Speaking & faculty fees$228,95881%
- Travel & lodging$44,46416%
- Food & beverage$8,9843%
- Education$3160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 192 | $214,349 |
| Otsuka America Pharmaceutical, Inc. | 96 | $66,044 |
| Alkermes, Inc. | 7 | $826 |
| Johnson & Johnson | 7 | $646 |
| E.r. Squibb & Sons, L.L.C. | 3 | $240 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $163 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $143 |
| Bioxcel Therapeutics, Inc. | 1 | $125 |
| Lundbeck LLC | 1 | $103 |
| SK Life Science, Inc. | 1 | $84 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$211,585
- ABILIFY MAINTENA$64,729
- ABILIFY ASIMTUFII$61,492
- ARISTADA$1,980
- LYBALVI$957
- INVEGA SUSTENNA$500
- ARISTADA INITIO$495
- REXULTI$480
- INVEGA TRINZA$250
- IGALMI$125
- COBENFY$123
- Austedo XR$122
- CAPLYTA$114
How this compares
$282,722 in reported general payments places this provider in the 95th percentile of 434 child & adolescent psychiatry providers in California.
See all child & adolescent psychiatry providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 35 | $110,215 |
| Abilify MaintenaAripiprazole | 11 | $27,810 |
| Clozapine | 120 | $4,756 |
| Olanzapine | 241 | $3,842 |
| Divalproex Sodium ErDivalproex Sodium | 41 | $2,549 |
| Divalproex Sodium | 93 | $2,003 |
| Risperidone | 96 | $1,185 |
| LoxapineLoxapine Succinate | 32 | $981 |
| Guanfacine Hcl | 49 | $898 |
| Haloperidol | 59 | $697 |
| Gabapentin | 55 | $676 |
| Bupropion XlBupropion Hcl | 51 | $608 |
| Lithium Carbonate | 106 | $562 |
| Sertraline Hcl | 69 | $554 |
| Aripiprazole | 43 | $433 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $646 | $110,21535 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $66,044 | $27,81011 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $214,349 | $98132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 434 child & adolescent psychiatry providers in California.
Other child & adolescent psychiatry in Fresno
- Nirmal BrarFresno$12K
- Indira AdapaFresno$7K
- Aubrey KingFresno$3K
- Kevin CoxOjai$2.9M
- Manpreet SinghSacramento$104K
- Ihab SolimanCorona del Mar$93K
- Syed NaqviLos Angeles$69K
- Ellen HeynemanSan Diego$62K
- Mark McDonaldLos Angeles$31K
- James HartmanDanville$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.